Keiretsu Forum - TYBE Health Investor Session: Deal Review and Q&A
Virtual event - Investment opportunity for members
REGISTER HERE for Zoom link
A special meeting where we will present the TYBR investment opportunity to the membership once again, now with a "Howard-approved" term sheet and diligence report.
This meeting is an excellent opportunity for you to meet our team, review the details of the deal, and address any remaining questions you may have. Your participation and feedback are highly valued as we approach this exciting stage of the investment process.
For brief summary of TYBR, please see below:
Startup Name: TYBR Health
Funding Round: Seed Prime Preferred Equity
Location: Houston, Texas
Current Round Size: $2M USD, $700K committed (including Mayo Clinic Ventures)
Funding raised to date: $3.9M + $750K Non-dilutive
Startup Space / Regulatory Path: Medical device / 510(k)
Focus: Post operative tissue protection
Current Highlights: Heading towards clinical pilot in Australia and FDA submission in Q4'2024.
TYBR Health has developed B3 GEL, the first versatile, flowable biologic barrier gel designed to protect healing tissues and prevent scarring and adhesions—common post-surgical complications that prolong recovery and drive up healthcare costs. Engineered for both open and minimally invasive procedures, B3 GEL initially focuses on tendon and ligament repairs, which are often associated with chronic stiffness and pain. With strong potential for expansion into other surgical applications, B3 GEL offers a scalable solution across multiple specialties. TYBR Health is backed by Y Combinator and Medtech Innovator.
